Thalidomide is now widely used to treat chronic graft-versus-host disease, but its use is associated with non-teratogenic side effects such as peripheral neuropathy. To examine the value of monitoring plasma concentrations of the drug in such patients, we have developed a high-performance liquid chromatographic (HPLC) assay. The method uses O·5 mL plasma, is linear to 10 mg/L and had a detection limit of O·2 mg/L. Thalidomide in plasma specimens was unstable at physiological pH but could be stabilized for several weeks by simple acidification. We describe a protocol for monitoring patients treated with thalidomide which permits convenient transportation and storage of specimens and report, provisionally, that plasma concentrations in the range 1-7 mg/L are therapeutically effective in chronic graft-versus-host disease without adverse side effects.
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Thalidomide (a-phthalimidoglutarimide) was withdrawn from use as a hypnotic in 1961 because of its teratogenicity. 1 However, there is continued interest in its immunosuppressive action in chronic graft-versus-host disease (GVHD). [2] [3] [4] [5] In this setting its usefulness is reduced by non-teratogenic side-effects, notably peripheral neuropathy. 6, 7 To minimize this risk we investigated the usefulness of monitoring plasma thalidomide concentrations in patients with chronic GVHD. Recently published assays are complex" or more appropriate to metabolite analysis." We decided that a simpler solution was to modify a high-performance liquid chromatography (HPLC) system already in development for the measurement of anticonvulsant drugs. Thalidomide is unstable in aqueous solutions and in plasma in vitro, 10, 11 necessitating immediate analysis; where this is Correspondence: Dr B J Boughton. impractical, transportation and storage of specimens presents problems. We have devised a simple protocol which overcomes these difficulties.
MATERIALS AND METHODS

Materials and equipment
Thalidomide was obtained from Penn Pharmaceuticals (High Wycombe, UK) and purity (National Standard: not less than 97%) was confirmed by melting-point determination, ultraviolet spectroscopy and nuclear magnetic resonance (NMR) spectroscopy. Methyl primidone (Gold Label, 99010 pure) was obtained from the Aldrich Chemical Co. (Gillingham, UK). HPLC-grade methanol and acetonitrile were obtained from Rathburn Chemicals (Walkerburn, UK). Pronalys AR grade chloroform, 1-4 dioxan, and Volucon 1·0 M HCl were obtained from Rhone-Poulenc (Manchester, UK). Ultra-pure FIGURE 1. Chromatograms of plasma extracts from two patients (a) taking thalidomide and (b) taking thalidomide and co-trimoxazole (trimethoprim + sulphamethoxazole). Thalidomide (T) eluted at 2 ·45 min, methyl primidone (Me-P) internal standard at 4· 77 min, sulphamethoxazole (8) In the preliminary studies specimens were transported immediately the 3· 5 miles (5' 5 km) to the Regional Laboratory for Toxicology at Dudley Road Hospital, where the blood was centrifuged without delay. Aliquots of plasma or serum were assayed for thalidomide immediately and after increasing intervals of storage at 23°C, 4°C and -12°C, and with and without the addition of I· 0 mol/L HCI.
In the final protocol, batches of 2 mL polypropylene screw-cap tubes, each containing 1·0 mL acidic internal standard solution, were supplied to the Haematology Laboratory at the Queen Elizabeth Hospital to enable on site processing as follows: blood (10 mL) was collected into lithium heparin and centrifuged within 15 min. Duplicate 500 JLL aliquots of plasma were transferred to separate 2 mL screwcap polypropylene tubes, each containing I· 0 mL acidic internal standard solution. The stabilized specimens were transported, at ambient temperature under routine conditions, to the Regional Laboratory for Toxicology where they were stored at 4°C prior to analysis.
The patient's stabilized plasma (in duplicate) and identically acidified horse plasma calibration standards were extracted for 10 min with 5 mL chloroform in borosilicate culture tubes. Following centrifugation, the aqueous phase was aspirated to waste, and the organic phase was filtered, evaporated to dryness at 50°C under air and reconstituted in 100 JLL methanol prior to chromatography. Figure 1 shows chromatograms for patients prescribed thalidomide alone, and thalidomide plus co-trimoxazole (trimethoprim and sulphamethoxazole). In the latter circumstance trimethoprim was not detected and the compound(s) eluting at 2 ·12 min remain unidentified. Plasma extracts from individuals receiving azathioprine produced a single peak, of Ann Clin Biochem 1995: 32 Methanolic stock solutions of thalidomide (50 mg/L) were stable for 36 months at 4 "C, as was the working internal standard solution (methyl primidone, 10 mg/L in 1·0 mollL HCI). In contrast, both plasma standards and patients' plasma lost all detectable thalidomide within 4 days at 4 "C. Figure 2 shows that unprocessed plasma from patients suffered a mean loss of 50% of the original thalidomide concentration over 6 h storage at 23 "C and 90% over 24 h. This was not prevented by use of fluoride oxalate as the plasma anticoagulant. Table I shows the effect on thalidomide concentration of four different treatments to a single plasma sample from each of four patients receiving the drug. Immediate acidification of plasma at 23 "C or freezing at -12 "C followed by storage for 7 h produced a result equal to that obtained following immediate acidification and extraction.
RESULTS
Single, acid-stabilized plasma specimens from eight patients had thalidomide concentrations, on initial assay, between O·4-2' 5 mg/L (mean 1·28 mg/L). Following storage at 23 "C for between 14-106 days (mean 43 days) replicate (acid-stabilized) aliquots had thalidomide concentrations between O·5-2' 8 mg/L (mean I' 26 mg/L); the difference between the two sets of results was not significant (paired t-test: P=0·98).
In three healthy male volunteers given a single dose of 200 mg thalidomide, plasma concentrations rose to maxima of I' 7, 1· 8 and 2·1 mg/L at 2, 3 and 4 h, respectively, and declined over 24 h to 0·2 mg/L, In five patients given 400 rng thalidomide, the plasma concentrations 10 h later ranged from 0·7 to 6· 0 mg/L. In two of these patients with normal gastrointestinal function the concentrations were 5· 0 and 6· 0 mg/L and in three with clinical Calibration was linear to 10 mg/L, with a detection limit of 0·2 mg/L. Recovery from augmented acid-stabilized drug-free plasma (both human and horse; n = 5 each) was 94070 at I' 0 mg/L and 971110 at 4· 0 mg/L; the extraction of thalidomide from acidified plasma into chloroform was cleaner and more efficient than into ethyl acetate.! For augmented, acidstabilized horse plasma coefficients of variation (n = 10) at 1·0 mg/L were 2'6% intra-batch and 4'5% inter-batch; at 4·0 mg/L, 0·9% and 1'8%, respectively. For a patient's plasma stabilized at the Queen Elizabeth Hospital and assayed at the Regional Toxicology Laboratory, coefficients of variation (n = 5) were 3·2% intra-batch and 5· 2% inter-batch at a thalidomide concentration of 2'1 mg/L. malabsorption syndrome due to GVHD the concentrations were 0'7,0'7 and 0·8 mg/L. In 10 patients with GVHD given 200-800 mg thalidomide daily and followed over 2-12 months, periodic thalidomide concentrations taken 10 h after dosing showed a maximum of 7·0 mg/L. The mucocutaneous features of GYHD improved and none showed any evidence of neuropathy.
DISCUSSION
'Two problems had to be addressed in developing .. practicable assay for thalidomide. The first arose from its instability at physiological pH, degradation of thalidomide in augmented plasma stored at -25°C for 34 days: 0·025 M citrate buffer was recommended as a stabilizing agent and was successfully applied to the assay of thalidomide in rat plasma. However, no practical proposals were made concerning how such a stabilizing agent might be used to simplify Ann Clin Biochem 1995: 32 handling of specimens from patients. The distribution and use on site of tubes containing acidic internal standard solution permits early and permanent stabilization of thalidomide in plasma specimens. In our experience, this has proved to be successful and free from the analytical error arising when two separate processing steps are required.
Eriksson et at.'? also referred to, but did not pursue, the second problem-that of assay specificity, the consequence (in part) of using a non-selective extraction procedure. Of the drugs commonly co-administered with thalidomide in GVHD, cyclosporin and penicillins are structurally distinct and do not interfere. Azathioprine produced a single plasma peak consistent with the parent compound which was readily separated from thalidomide. The greatest potential for interference with the chromatography came from sulphamethoxazole and especially the unidentified coextracted substance associated with it in patients' plasma, but not present in solutions of pure drug. The need to resolve thalidomide from these compounds determined the choice of mobile phase. Our procedure is simpler and chromatographically more efficient than the gradient elution approach of Chen et al.S and faster than that of Heney et at."
In common with the most recently reported methods for thalidomide analysis,S,12,13 the assay described here does not detect thalidomide metabolites. Czejka and Koch.? whose analytical approach does extract these polar compounds, suggested that parent substance alone is of pharmacological interest. This is disputed by Wood and Proctor;" who proposed a role for an active metabolite. However, their hypothesis is tentative and the exact immunosuppressive action of thalidomide remains unclear.
In the clinical studies we performed, the problem of drowsiness was ameliorated by administering the drug once daily at 22·00 h. Plasma sampling for the measurement of thalidomide concentration was then conveniently carried out the following morning, 10 h after the dose. Plasma monitoring in patients and control subjects showed a rise in plasma concentrations for 4 h and then a decline to near baseline values over 24 h. Using the assay described above, a clinical response was observed in 10 patients with chronic GYHD monitored for 2-12 months; during this period the maximum plasma concentration observed was 7· 0 mg/L. Although toxicity has yet to be shown to correlate with plasma concentrations, it would seem reasonable at this stage, to suggest that plasma concentrations be kept below 7· 0 mg/L for efficacy without toxicity.
